Nucleix Adds $55M To Support EpiCheck Lung Cancer Test

 
• By Reed Miller

The new money will help the company advance its unique EpiCheck technology for detecting cancer-specific-changes to DNA called methylation.

Lung Cancer
• Source: shutterstock.com

Nucleix has completed a $55M funding round to advance its Lung EpiCheck liquid-biopsy test for the early detection of lung cancer.

The oversubscribed funding round, announced on 7 April, is led by RA Capital Management, with participation from BlackRock, Lilly Asia...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

GE HealthCare Launches Intraoperative Ultrasound Product Series: bkActiv S

 
• By Natasha Barrow

GE HealthCare launches bkActiv S series – part of the bkPortfolio family of Active Imaging systems.

EU Pilot Features ‘All-In-One’ Regulatory Path For Drug/Diagnostic Trials

 
• By Vibha Sharma

The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 
• By Natasha Barrow

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.